JAZZ vs MD · P/E 1988, rev $4.07B vs P/E 11, $1.93B cap
Jazz Pharmaceuticals PLC (JAZZ) versus Mednax Inc (MD) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Mednax Inc (MD) is a medical care facilities company listed on NYSE.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
MD does not have a complete income-statement cache yet.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. MD currently screens at market cap $1.93B and trailing P/E 11.4.
Not investment advice. Open the JAZZ and MD stock pages for the full models.
Not investment advice.